GLP-1 Drugs and Body Positivity

How Do GLP-1 Drugs Like Ozempic and Mounjaro Actually Work?

Glucagon-like peptide-1 (GLP-1) receptor agonists were originally developed to treat type 2 diabetes. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, and tirzepatide (Mounjaro/Zepbound), which acts on both GLP-1 and GIP receptors, work by mimicking incretin hormones the gut releases after eating. They slow gastric emptying, enhance insulin secretion, and act on appetite-regulating regions of the brain to reduce hunger and food cravings.

Clinical trials including the STEP program for semaglutide and SURMOUNT trials for tirzepatide have shown average body weight reductions of approximately 15% to 22% over roughly 16 months, results that previously were only achievable through bariatric surgery. The World Health Organization classifies obesity as a chronic, relapsing disease, and major medical bodies including the American Diabetes Association and the Obesity Society now recognize GLP-1 therapy as a first-line pharmacological option for eligible patients.

What Does the Rise of Weight Loss Drugs Mean for the Body Positivity Movement?

The body positivity movement, which grew from fat acceptance activism in the late 20th century, holds that weight stigma causes measurable harm and that body diversity should be celebrated. Advocates point to research, including studies cited by the American Psychological Association, showing weight discrimination is associated with worse mental and physical health outcomes independent of body mass index. Critics of the GLP-1 boom worry that mass adoption of weight loss drugs may intensify pressure to conform to thin ideals and erode hard-won progress on size acceptance.

Obesity medicine specialists counter that recognising obesity as a treatable medical condition is not in conflict with respecting people of all body sizes. They argue that withholding effective treatment from patients who want it is itself a form of stigma. Public health experts increasingly advocate a both-and approach: combating weight-based discrimination in healthcare, employment, and media while ensuring equitable access to evidence-based obesity treatments for those who choose them.

What Are the Known Risks and Limitations of GLP-1 Therapy?

The most common adverse effects of GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, which usually improve over weeks. The FDA prescribing information includes warnings about pancreatitis, gallbladder disease, and a boxed warning regarding thyroid C-cell tumours observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take these medications.

Real-world evidence and extension studies, including the STEP 4 trial, indicate that stopping treatment typically results in regain of much of the lost weight, suggesting that obesity, like hypertension or diabetes, may require long-term pharmacological management. Cost and insurance coverage remain significant barriers, and global supply has at times struggled to meet demand. Researchers are also investigating broader effects of GLP-1 drugs on cardiovascular outcomes, kidney disease, and addiction-related behaviours.